These studies suggested the existence of an IRF5-IRF4 regulatory axis in which IRF5 signaling mediates microglial pro-inflammatory responses and IRF4 signaling enhances microglial anti-inflammatory activation, and as a result, the IRF5-IRF4 regulatory axis impacts stroke outcomes. The gene discussed is IRF5; the disease is stroke disorder.